For the third quarter, Quest posted revenue of $2.79 billion, up 42.5% compared with revenue of $1.95 billion in the same period the year before. The company's net income for the most recent period was $591 million, compared with $226 million in the third quarter of fiscal 2019.

Quest has performed over 22 million COVID-19 molecular and serology tests to date. The firm also noticed that its base testing volume, which excludes COVID-19 molecular and antibody testing, continued to recover throughout the third quarter.

Quest is raising its full-year 2020 outlook given its year-to-date performance and a clearer line of sight for both the base business and COVID-19 testing, the firm said.

Anthem, Quest ink partnership
Anthem and Quest Diagnostics have announced a collaboration to improve healthcare delivery for both providers and patients.

Quest wins approval to increase capacity for COVID-19
Quest Diagnostics has received emergency use authorization from the U.S. Food and Drug Administration to test a new laboratory technique that could bolster...

FDA grants first coronavirus clearance for sample pooling to Quest
The U.S. Food and Drug Administration has granted Quest Diagnostics the first emergency use authorization for a SARS-CoV-2 molecular diagnostic for testing...

Quest overall testing volume, revenue decline
Quest Diagnostics reported an 18% decline in overall test volume as part of a look at its preliminary financial results from the second quarter and reported...

HPV, Pap cotesting best for cervical cancer detection in Quest study
Human papillomavirus (HPV) or Pap testing alone is less likely than the combination of both methods to detect cervical cancer, according to a Quest Diagnostics...